Heska Corp (NASDAQ:HSKA) released its earnings results on Tuesday. The company reported $0.46 EPS for the quarter, topping analysts’ consensus estimates of $0.37 by $0.09. Heska Corp had a return on equity of 10.46% and a net margin of 7.55%. The company had revenue of $39.50 million for the quarter, compared to the consensus estimate of $34.56 million. The company’s quarterly revenue was up 32.6% on a year-over-year basis.
Shares of Heska Corp (NASDAQ:HSKA) traded down 1.25% during mid-day trading on Friday, hitting $103.10. The company had a trading volume of 79,484 shares. The firm has a market cap of $727.06 million, a PE ratio of 72.10 and a beta of 0.83. The firm’s 50 day moving average is $88.91 and its 200-day moving average is $70.16. Heska Corp has a 12-month low of $26.25 and a 12-month high of $105.00.
In other news, CFO John Mcmahon sold 708 shares of Heska Corp stock in a transaction dated Thursday, March 9th. The stock was sold at an average price of $97.42, for a total value of $68,973.36. Following the transaction, the chief financial officer now directly owns 200 shares in the company, valued at $19,484. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Rod Lippincott sold 5,157 shares of Heska Corp stock in a transaction dated Thursday, March 9th. The stock was sold at an average price of $97.87, for a total value of $504,715.59. Following the completion of the transaction, the executive vice president now owns 10,513 shares in the company, valued at $1,028,907.31. The disclosure for this sale can be found here. Insiders sold 18,865 shares of company stock worth $1,667,339 over the last quarter. 15.30% of the stock is currently owned by corporate insiders.
Institutional investors have recently bought and sold shares of the company. MSI Financial Services Inc bought a new stake in Heska Corp during the third quarter valued at about $103,000. Two Sigma Securities LLC bought a new stake in Heska Corp during the third quarter valued at about $244,000. Metropolitan Life Insurance Co. NY boosted its stake in Heska Corp by 7.1% in the second quarter. Metropolitan Life Insurance Co. NY now owns 4,853 shares of the company’s stock valued at $180,000 after buying an additional 320 shares during the last quarter. BlackRock Inc. boosted its stake in Heska Corp by 6.2% in the third quarter. BlackRock Inc. now owns 5,413 shares of the company’s stock valued at $295,000 after buying an additional 318 shares during the last quarter. Finally, Elkfork Partners LLC bought a new stake in Heska Corp during the fourth quarter valued at about $495,000. Institutional investors and hedge funds own 77.40% of the company’s stock.
A number of research firms have commented on HSKA. Zacks Investment Research raised Heska Corp from a “hold” rating to a “buy” rating and set a $102.00 target price on the stock in a report on Thursday, March 2nd. Benchmark Co. raised their price target on Heska Corp from $78.00 to $100.00 and gave the stock a “hold” rating in a report on Monday, February 6th. B. Riley reissued a “neutral” rating and issued a $83.00 price target on shares of Heska Corp in a report on Wednesday, March 1st. Finally, CL King downgraded Heska Corp from a “buy” rating to a “neutral” rating in a report on Thursday, January 26th. Four analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $90.50.
About Heska Corp
Heska Corporation develops, manufactures, markets, sells and supports veterinary products. The Company focuses on the canine and feline companion animal health markets. Its segments include Core Companion Animal Health segment, which includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, and single use products and services, such as heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing, and Other Vaccines, Pharmaceuticals and Products segment, which includes private label vaccine and pharmaceutical production, primarily for cattle but also for other animals, including small mammals.
Receive News & Ratings for Heska Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska Corp and related companies with MarketBeat.com's FREE daily email newsletter.